PortalPublikationenEfficacy of Catheter Ablation for Atrial Arrhythmias in Pati...

Efficacy of Catheter Ablation for Atrial Arrhythmias in Patients with Arrhythmogenic Right Ventricular Cardiomyopathy-A Multicenter Study

Standard

Efficacy of Catheter Ablation for Atrial Arrhythmias in Patients with Arrhythmogenic Right Ventricular Cardiomyopathy-A Multicenter Study. / Gasperetti, Alessio; James, Cynthia A; Chen, Liang; Schenker, Niklas; Casella, Michela; Kany, Shinwan; Mathew, Shibu; Compagnucci, Paolo; Müssigbrodt, Andreas; Jensen, Henrik K; Svensson, Anneli; Costa, Sarah; Forleo, Giovanni B; Platonov, Pyotr G; Tondo, Claudio; Song, Jiang-Ping; Dello Russo, Antonio; Ruschitzka, Frank; Brunckhorst, Corinna; Calkins, Hugh; Duru, Firat; Saguner, Ardan M.

in: J CLIN MED, Jahrgang 10, Nr. 21, 4962, 26.10.2021.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Gasperetti, A, James, CA, Chen, L, Schenker, N, Casella, M, Kany, S, Mathew, S, Compagnucci, P, Müssigbrodt, A, Jensen, HK, Svensson, A, Costa, S, Forleo, GB, Platonov, PG, Tondo, C, Song, J-P, Dello Russo, A, Ruschitzka, F, Brunckhorst, C, Calkins, H, Duru, F & Saguner, AM 2021, 'Efficacy of Catheter Ablation for Atrial Arrhythmias in Patients with Arrhythmogenic Right Ventricular Cardiomyopathy-A Multicenter Study', J CLIN MED, Jg. 10, Nr. 21, 4962. https://doi.org/10.3390/jcm10214962

APA

Gasperetti, A., James, C. A., Chen, L., Schenker, N., Casella, M., Kany, S., Mathew, S., Compagnucci, P., Müssigbrodt, A., Jensen, H. K., Svensson, A., Costa, S., Forleo, G. B., Platonov, P. G., Tondo, C., Song, J-P., Dello Russo, A., Ruschitzka, F., Brunckhorst, C., ... Saguner, A. M. (2021). Efficacy of Catheter Ablation for Atrial Arrhythmias in Patients with Arrhythmogenic Right Ventricular Cardiomyopathy-A Multicenter Study. J CLIN MED, 10(21), [4962]. https://doi.org/10.3390/jcm10214962

Vancouver

Gasperetti A, James CA, Chen L, Schenker N, Casella M, Kany S et al. Efficacy of Catheter Ablation for Atrial Arrhythmias in Patients with Arrhythmogenic Right Ventricular Cardiomyopathy-A Multicenter Study. J CLIN MED. 2021 Okt 26;10(21). 4962. https://doi.org/10.3390/jcm10214962

Bibtex

@article{ad53fce4b1cf48029700a23feae13dba,
title = "Efficacy of Catheter Ablation for Atrial Arrhythmias in Patients with Arrhythmogenic Right Ventricular Cardiomyopathy-A Multicenter Study",
abstract = "Background: Atrial arrhythmias are present in up to 20% of patients with arrhythmogenic right ventricular cardiomyopathy (ARVC). Catheter ablation (CA) is an effective treatment for atrial arrhythmias in the general population. Data regarding CA for atrial arrhythmias in ARVC are scarce. Objective: To assess the safety and efficacy of CA for atrial arrhythmias in patients with ARVC. Methods: In this international collaborative effort, all patients with a definite diagnosis of ARVC undergoing CA for atrial fibrillation (AF), focal atrial tachycardia (AT), or cavotricuspid isthmus (CTI)-dependent atrial flutter (AFl) were extracted from twelve ARVC registries. Demographic, periprocedural, and long-term arrhythmic outcome data were collected. Results: Thirty-seven patients were enrolled in the study (age 50.2 ± 16.6 years, male 84%, CHA2DS2VASc 1 (1,2), HAS-BLED 0 (0-2)). The arrhythmia leading to CA was AF in 23 (62%), focal left AT in 5 (14%), and CTI-dependent AFl in 9 (24%). Acute procedural success was achieved in all procedures but one (n = 1 focal left AT; 97% acute success). The median follow-up period was 27 (13-67) months, and 96%, 74%, and 61% of patients undergoing AF ablation were free from any atrial arrhythmia recurrence after a single procedure at 6 months, 12 months, and last follow-up, respectively. After focal AT ablation, freedom from atrial arrhythmia recurrence was 80%, 80%, and 60% at 6 months, 12 months, and last follow-up, respectively. All patients undergoing CTI ablation were free from atrial arrhythmia recurrences at 6 months, with 89% single-procedural arrhythmic freedom at last follow-up. One major complication (2.7%; PV stenosis requiring PV stenting) occurred. Conclusions: CA is safe and effective in managing atrial arrhythmias in patients with ARVC, with success rates comparable to the general population.",
author = "Alessio Gasperetti and James, {Cynthia A} and Liang Chen and Niklas Schenker and Michela Casella and Shinwan Kany and Shibu Mathew and Paolo Compagnucci and Andreas M{\"u}ssigbrodt and Jensen, {Henrik K} and Anneli Svensson and Sarah Costa and Forleo, {Giovanni B} and Platonov, {Pyotr G} and Claudio Tondo and Jiang-Ping Song and {Dello Russo}, Antonio and Frank Ruschitzka and Corinna Brunckhorst and Hugh Calkins and Firat Duru and Saguner, {Ardan M}",
year = "2021",
month = oct,
day = "26",
doi = "10.3390/jcm10214962",
language = "English",
volume = "10",
journal = "J CLIN MED",
issn = "2077-0383",
publisher = "MDPI AG",
number = "21",

}

RIS

TY - JOUR

T1 - Efficacy of Catheter Ablation for Atrial Arrhythmias in Patients with Arrhythmogenic Right Ventricular Cardiomyopathy-A Multicenter Study

AU - Gasperetti, Alessio

AU - James, Cynthia A

AU - Chen, Liang

AU - Schenker, Niklas

AU - Casella, Michela

AU - Kany, Shinwan

AU - Mathew, Shibu

AU - Compagnucci, Paolo

AU - Müssigbrodt, Andreas

AU - Jensen, Henrik K

AU - Svensson, Anneli

AU - Costa, Sarah

AU - Forleo, Giovanni B

AU - Platonov, Pyotr G

AU - Tondo, Claudio

AU - Song, Jiang-Ping

AU - Dello Russo, Antonio

AU - Ruschitzka, Frank

AU - Brunckhorst, Corinna

AU - Calkins, Hugh

AU - Duru, Firat

AU - Saguner, Ardan M

PY - 2021/10/26

Y1 - 2021/10/26

N2 - Background: Atrial arrhythmias are present in up to 20% of patients with arrhythmogenic right ventricular cardiomyopathy (ARVC). Catheter ablation (CA) is an effective treatment for atrial arrhythmias in the general population. Data regarding CA for atrial arrhythmias in ARVC are scarce. Objective: To assess the safety and efficacy of CA for atrial arrhythmias in patients with ARVC. Methods: In this international collaborative effort, all patients with a definite diagnosis of ARVC undergoing CA for atrial fibrillation (AF), focal atrial tachycardia (AT), or cavotricuspid isthmus (CTI)-dependent atrial flutter (AFl) were extracted from twelve ARVC registries. Demographic, periprocedural, and long-term arrhythmic outcome data were collected. Results: Thirty-seven patients were enrolled in the study (age 50.2 ± 16.6 years, male 84%, CHA2DS2VASc 1 (1,2), HAS-BLED 0 (0-2)). The arrhythmia leading to CA was AF in 23 (62%), focal left AT in 5 (14%), and CTI-dependent AFl in 9 (24%). Acute procedural success was achieved in all procedures but one (n = 1 focal left AT; 97% acute success). The median follow-up period was 27 (13-67) months, and 96%, 74%, and 61% of patients undergoing AF ablation were free from any atrial arrhythmia recurrence after a single procedure at 6 months, 12 months, and last follow-up, respectively. After focal AT ablation, freedom from atrial arrhythmia recurrence was 80%, 80%, and 60% at 6 months, 12 months, and last follow-up, respectively. All patients undergoing CTI ablation were free from atrial arrhythmia recurrences at 6 months, with 89% single-procedural arrhythmic freedom at last follow-up. One major complication (2.7%; PV stenosis requiring PV stenting) occurred. Conclusions: CA is safe and effective in managing atrial arrhythmias in patients with ARVC, with success rates comparable to the general population.

AB - Background: Atrial arrhythmias are present in up to 20% of patients with arrhythmogenic right ventricular cardiomyopathy (ARVC). Catheter ablation (CA) is an effective treatment for atrial arrhythmias in the general population. Data regarding CA for atrial arrhythmias in ARVC are scarce. Objective: To assess the safety and efficacy of CA for atrial arrhythmias in patients with ARVC. Methods: In this international collaborative effort, all patients with a definite diagnosis of ARVC undergoing CA for atrial fibrillation (AF), focal atrial tachycardia (AT), or cavotricuspid isthmus (CTI)-dependent atrial flutter (AFl) were extracted from twelve ARVC registries. Demographic, periprocedural, and long-term arrhythmic outcome data were collected. Results: Thirty-seven patients were enrolled in the study (age 50.2 ± 16.6 years, male 84%, CHA2DS2VASc 1 (1,2), HAS-BLED 0 (0-2)). The arrhythmia leading to CA was AF in 23 (62%), focal left AT in 5 (14%), and CTI-dependent AFl in 9 (24%). Acute procedural success was achieved in all procedures but one (n = 1 focal left AT; 97% acute success). The median follow-up period was 27 (13-67) months, and 96%, 74%, and 61% of patients undergoing AF ablation were free from any atrial arrhythmia recurrence after a single procedure at 6 months, 12 months, and last follow-up, respectively. After focal AT ablation, freedom from atrial arrhythmia recurrence was 80%, 80%, and 60% at 6 months, 12 months, and last follow-up, respectively. All patients undergoing CTI ablation were free from atrial arrhythmia recurrences at 6 months, with 89% single-procedural arrhythmic freedom at last follow-up. One major complication (2.7%; PV stenosis requiring PV stenting) occurred. Conclusions: CA is safe and effective in managing atrial arrhythmias in patients with ARVC, with success rates comparable to the general population.

U2 - 10.3390/jcm10214962

DO - 10.3390/jcm10214962

M3 - SCORING: Journal article

C2 - 34768482

VL - 10

JO - J CLIN MED

JF - J CLIN MED

SN - 2077-0383

IS - 21

M1 - 4962

ER -